Cambridge Investment Research Advisors Inc. lessened its position in Opko Health, Inc. (NASDAQ:OPK) by 2.0% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 479,443 shares of the biotechnology company’s stock after selling 10,000 shares during the period. Cambridge Investment Research Advisors Inc. owned approximately 0.09% of Opko Health worth $3,289,000 as of its most recent filing with the SEC.

A number of other large investors have also recently modified their holdings of OPK. Teachers Advisors LLC increased its stake in Opko Health by 3.0% in the first quarter. Teachers Advisors LLC now owns 405,251 shares of the biotechnology company’s stock valued at $3,242,000 after purchasing an additional 11,782 shares in the last quarter. Legal & General Group Plc increased its stake in Opko Health by 217.4% in the first quarter. Legal & General Group Plc now owns 111,673 shares of the biotechnology company’s stock valued at $893,000 after purchasing an additional 76,487 shares in the last quarter. Dimensional Fund Advisors LP increased its stake in Opko Health by 2.0% in the first quarter. Dimensional Fund Advisors LP now owns 1,621,128 shares of the biotechnology company’s stock valued at $12,968,000 after purchasing an additional 31,225 shares in the last quarter. BlackRock Inc. increased its stake in Opko Health by 11,481.3% in the first quarter. BlackRock Inc. now owns 22,645,285 shares of the biotechnology company’s stock valued at $181,163,000 after purchasing an additional 22,449,752 shares in the last quarter. Finally, Credit Suisse AG increased its stake in Opko Health by 122.0% in the first quarter. Credit Suisse AG now owns 746,958 shares of the biotechnology company’s stock valued at $5,976,000 after purchasing an additional 410,445 shares in the last quarter. 22.66% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: “Opko Health, Inc. (OPK) Holdings Reduced by Cambridge Investment Research Advisors Inc.” was posted by Watch List News and is the property of of Watch List News. If you are accessing this piece on another website, it was illegally stolen and republished in violation of U.S. and international trademark and copyright law. The correct version of this piece can be read at https://www.watchlistnews.com/opko-health-inc-opk-holdings-reduced-by-cambridge-investment-research-advisors-inc/1711954.html.

In other Opko Health news, major shareholder Opko Health, Inc. bought 655,738 shares of Opko Health stock in a transaction that occurred on Monday, October 30th. The stock was acquired at an average price of $3.05 per share, for a total transaction of $2,000,000.90. Following the completion of the acquisition, the insider now owns 6,678,752 shares of the company’s stock, valued at approximately $20,370,193.60. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Phillip Md Et Al Frost bought 260,000 shares of Opko Health stock in a transaction that occurred on Thursday, September 14th. The shares were acquired at an average price of $5.98 per share, with a total value of $1,554,800.00. Following the acquisition, the chief executive officer now directly owns 3,068,951 shares of the company’s stock, valued at approximately $18,352,326.98. The disclosure for this purchase can be found here. Insiders have purchased 1,126,038 shares of company stock valued at $4,828,540 in the last 90 days. 40.19% of the stock is currently owned by corporate insiders.

Shares of Opko Health, Inc. (NASDAQ:OPK) traded up $0.07 during mid-day trading on Friday, hitting $4.94. 6,014,604 shares of the stock traded hands, compared to its average volume of 4,554,437. The company has a quick ratio of 1.48, a current ratio of 1.66 and a debt-to-equity ratio of 0.01. Opko Health, Inc. has a 52 week low of $4.50 and a 52 week high of $12.15.

Opko Health (NASDAQ:OPK) last announced its earnings results on Wednesday, November 8th. The biotechnology company reported ($0.08) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.05) by ($0.03). Opko Health had a negative return on equity of 5.17% and a negative net margin of 9.45%. The business had revenue of $263.50 million for the quarter, compared to analyst estimates of $319.43 million. During the same quarter in the previous year, the company posted ($0.03) EPS. The business’s revenue for the quarter was down 11.6% compared to the same quarter last year. research analysts anticipate that Opko Health, Inc. will post -0.27 EPS for the current fiscal year.

OPK has been the subject of several recent analyst reports. Ladenburg Thalmann Financial Services reaffirmed a “buy” rating and issued a $16.00 target price on shares of Opko Health in a research note on Monday, September 25th. Cantor Fitzgerald set a $20.00 price objective on shares of Opko Health and gave the stock a “buy” rating in a research report on Thursday, October 12th. Zacks Investment Research raised shares of Opko Health from a “hold” rating to a “buy” rating and set a $7.25 price objective for the company in a research report on Friday, July 21st. Jefferies Group LLC reissued a “hold” rating and set a $8.00 price objective on shares of Opko Health in a research report on Thursday, July 27th. Finally, BidaskClub raised shares of Opko Health from a “sell” rating to a “hold” rating in a research report on Monday, July 24th. Two research analysts have rated the stock with a sell rating, two have given a hold rating and six have assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $13.97.

Opko Health Profile

OPKO Health, Inc is a healthcare company. Its segments include Pharmaceutical, Diagnostics and Corporate. Pharmaceutical consists of the pharmaceutical operations in Chile, Mexico, Ireland, Israel and Spain and its pharmaceutical research and development operations. Diagnostics consists of the clinical laboratory operations in Bio-Reference Laboratories (Bio-Reference) and its point-of-care operations.

Want to see what other hedge funds are holding OPK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Opko Health, Inc. (NASDAQ:OPK).

Institutional Ownership by Quarter for Opko Health (NASDAQ:OPK)

Receive News & Ratings for Opko Health Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.